stockrowAxsome Therapeutics, Inc.
AXSM Healthcare Biotechnology
Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +73.9%
- Free cash flow
- −1,078.3%
- Total debt
- +4.04%
Quarter to September 2026, against a year earlier
Follow AXSM
Alert me
Axsome Therapeutics, Inc. (AXSM) Free cash flow
Axsome Therapeutics, Inc.'s free cash flow for fiscal 2025 was −$93.9M, compared with −$128.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$82.6M. Over the past ten years it has ranged from −$145.7M (fiscal 2023) to −$7.5M (fiscal 2015); the current reading is higher than 45% of that period. Axsome Therapeutics, Inc. ranks 421st of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$93.9M | — |
| FY2024 | −$128.7M | — |
| FY2023 | −$145.7M | — |
| FY2022 | −$117.2M | — |
| FY2021 | −$108.5M | — |
| FY2020 | −$78.5M | — |
| FY2019 | −$46.4M | — |
| FY2018 | −$30.1M | — |
| FY2017 | −$26.5M | — |
| FY2016 | −$21.4M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | −$9.7M | — |
| Jun 2026 | −$33.4M | — |
| Mar 2026 | −$20.8M | — |
| Dec 2025 | −$18.7M | — |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $79.8M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$66.6M |
| RYTM Rhythm Pharmaceuticals, Inc. compare | −$81.8M |
| AXSM Axsome Therapeutics, Inc. | −$82.6M |
| ORKA Oruka Therapeutics, Inc. compare | −$101.2M |
| ABVX Abivax SA Sponsored ADR compare | −$226.1M |
| PRAX Praxis Precision Medicines, Inc. compare | −$306.2M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$308.9M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$567.5M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on AXSM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement